Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look ...

CVS Caremark has removed coverage of Zepbound, a GLP-1 weight-loss drug, citing pricing concerns and shifting payer dynamics ...

Investing.com - TD Cowen维持了对CVS Health (NYSE: CVS )的买入评级和95.00美元的目标价，表示该公司可能从Centene (NYSE: CNC )面临的挑战中受益。根据 InvestingPro 数据，Centene目前的市盈率为5.23，分析师目标价在45美元至92美元之间，反映了市场在当前挑战下的复杂情绪。

芝加哥 - 年收入超过376亿美元、根据 InvestingPro 分析目前被低估的医疗保健巨头CVS Health (NYSE: CVS )周四在芝加哥浸信会学院开设了一个新的劳动力创新和人才中心 (WITC)，旨在为社区成员提供就业培训。

CVS Health (CVS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some ...

This action was surfaced by Law.com Radar, which delivers real-time alerting on new litigation across more than 2,900 state ...

CVS Health Corporation (NYSE:CVS) is one of the Best Dividend Stocks of 2025. Following a challenging year in 2024, CVS ...

2025年6月30日，药品零售公司西维斯（CVS）成交额为4.14亿美元，在当日美股中排第259名，成交额较昨日增加1.92%，当日成交量为602.19万。 西维斯（CVS）于2025年6月30日涨0.72%，报68.98美元，该股过去5个交易日涨3.25%，整个6月涨7.71%，年初至今涨53.66%，过去52周涨16.80%。 *如果公司上市时间少于52周，则52周涨跌幅为上市至今涨跌幅（同样 ...

CVS Health's pharmacy benefit manager unit must pay the U.S. government $95 million after a federal judge found it ...

In the assessment of 12-month price targets, analysts unveil insights for CVS Health, presenting an average target of $79.0, ...